Literature DB >> 18358702

Antimicrobial optimisation in secondary care: the pharmacist as part of a multidisciplinary antimicrobial programme--a literature review.

Antonella P Tonna1, Derek Stewart, Bernice West, Ian Gould, Dorothy McCaig.   

Abstract

The aims of this literature review were: (i) to determine what roles have been supported by evidence for the pharmacist in optimising antimicrobial treatment as part of an antimicrobial multidisciplinary team (AMDT) in secondary care; and (ii) to describe the outcomes of interventions of an AMDT in secondary care with pharmacy involvement. Both descriptive and primary research reports were identified and included. The hospital pharmacist emerged as a key member of the AMDT. The dispensary pharmacist was mainly involved in the screening processes and was crucial in implementing restriction policies. The general ward-based clinical pharmacist was involved in guideline development, formulary management, intravenous-to-oral conversions and evaluations of programme outcomes through monitoring of drug usage, and also facilitated identification of patients with specific needs who could be referred to the specialist pharmacist. A role emerged for the specialist pharmacist who was an integral part of the AMDT and was involved in activities including reviewing of more complex patients, attending ward rounds and streamlining of initial empirical antimicrobial treatment. Outcomes of interventions reported in primary research have been classified into: drug outcomes, where most trials measured and reported an increase in adherence to guidelines; microbiological outcomes, only considered in a few trials; clinical outcomes, with different parameters measured and a maintenance or improvement reported; and financial outcomes. The latter were reported in all trials with numerous cost savings, although not all were statistically significant. Moreover, the cost of the intervention was not always considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358702     DOI: 10.1016/j.ijantimicag.2008.01.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  A cross-sectional survey of the profile and activities of Antimicrobial Management Teams in Irish Hospitals.

Authors:  Aoife Fleming; Antonella Tonna; Sile O'Connor; Stephen Byrne; Derek Stewart
Journal:  Int J Clin Pharm       Date:  2014-01-03

2.  Clinical pharmacists' interventions in a German university hospital.

Authors:  Claudia Langebrake; Heike Hilgarth
Journal:  Pharm World Sci       Date:  2010-01-19

Review 3.  Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000-2010).

Authors:  Inajara Rotta; Teresa M Salgado; Maria Lara Silva; Cassyano J Correr; Fernando Fernandez-Llimos
Journal:  Int J Clin Pharm       Date:  2015-05-23

4.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

5.  The effect of a whole-system approach in an antimicrobial stewardship programme at the Singapore General Hospital.

Authors:  J Teo; A L H Kwa; J Loh; M P Chlebicki; W Lee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-10       Impact factor: 3.267

6.  Roles of Infectious Diseases Consultant Pharmacists and Antimicrobial Stewardship Pharmacists: A Survey of Canadian Tertiary Care Academic Hospitals.

Authors:  Jessica E Beach; Tasha D Ramsey; Sean K Gorman; Tim T Y Lau
Journal:  Can J Hosp Pharm       Date:  2017-12-21

7.  What role do pharmacists play in mediating antibiotic use in hospitals? A qualitative study.

Authors:  Alex Broom; Jennifer Broom; Emma Kirby; Stefanie Plage; Jon Adams
Journal:  BMJ Open       Date:  2015-11-03       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.